Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07312513

Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds

The aim of this post market clinical follow up (PMCF) study is to confirm the performance of Debrisoft® Duo, to collect safety data regarding expected adverse events and to detect potential unexpected adverse events associated with the use of Debrisoft® Duo within the certified indications and under the conditions of routine use.

Recruiting

Interested in participating?

Request Info

Key information

About this study

This clinical investigation will be conducted as multicenter, randomized in parallel groups, non-inferiority controlled trial. After randomization patients will receive wound debrided with the investigational device or the comparator device during one study visit. During the study visit patients will have clinical examination and wound photos will be taken.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Patient is legally capable
  • Patient has signed written informed consent
  • Presence of one of the following wounds
  • Venous lower leg ulcer
  • Arterial ulcer
  • Diabetic ulcer
  • Pressure ulcer
  • Post-operative wound healing by secondary intention
  • Traumatic wound
  • Surgical wound
  • Burn or scald (grade III: after surgical debridement)
  • Epidermolysis Bullosa
  • Wound area >4cm2
  • The entire wound area can be displayed on one photo from a distance of 25-30 cm
  • Covered with at least 30% debris, necrosis, slough, fibrotic tissue

Exclusion criteria

  • Known allergy and/or hypersensitivity to Debrisoft® Duo or any of the product components
  • Pregnancy or breast feeding
  • Patient is illiterate
  • Participation in a interventional clinical trial within the last 14 days and during participation in this study
  • Any other medical condition, which, by opinion of the investigator, may have impact of the success of the study treatment and/ or interpretation of the study results
  • severe pain or hyperesthesia in the wound area
  • history of drug or alcohol abuse
  • chronic analgesic use (especially opioids) that could influence baseline pain perception
  • cognitive impairment, which may affect the ability to accurately self-report pain
  • Use of anaesthesia before the debridment procedure
  • presence of hard necrotic tissue or other tissue which should not be debrided in general. Other types of hard necrotic tissue requiring debridement, as determined by the investigator, are permitted and may be also pre-moistened before the procedure if deemed necessary

Treatment and study plan

two sided debridement pad

Device

two sided debridement pad

one sided debridment pad

Device

one sided debridment pad

Primary outcomes

  1. Relative reduction of fibrinous and necrotic tissue/slough/debris measured by W.H.A.T.

    Time frame: 1 day

    Wound photos will be taken. On these photos, the amount of fibrinous and necrotic tissue/slough/debris in the wound bed before and after debridement will be measured by W.H.A.T. (Wound Healing Analyzing Tool).

Secondary outcomes

  1. Relative reduction of fibrinous and necrotic tissue/slough/debris measured by he investigator

    Time frame: 1 day

    The amount of fibrinous and necrotic tissue/slough/debris in the wound bed before and after debridement will be measured by the investigator.

  2. Rate of device-related adverse events (device safety)

    Time frame: 1 day

    Frequency and character of device deficiencies (DDs), adverse events (AEs), serious adverse events (SAEs), adverse device effects (ADEs), serious adverse device effects (SADEs) and incidents.

  3. Change of wound bed condition, defined by the combination of the following parameters:

    Time frame: 1 day

    • Change in grade of exudate (from very high to none)
    • Change in type of exudate (from haemorrhagic to serous)
    • Change of the wound surrounding skin (presence or abscence of normal, erosive, dry/scaling, dry cracking, oeadematous, red or discoloured skin and cream residues)
    • Change of the wound bed and wound edges (presence or abscence of debris, discoloration, maceration, hyperkeratosis, smooth skin, thickened/rolled edges, undermining, vital tissue, biofilm)
    • Removal of biofilm (estimated by the user)
  4. Wound related pain

    Time frame: 1 day

    Wound related pain will be measured directly before, during and 10 +/-2 minutes using NRS-11 scale

  5. Time needed for debridement

    Time frame: 1 day

    Time needed for the debridement procedure will be assessed using a stopper

  6. Amount of products

    Time frame: 1 day

    Amount of products that were used during one debridement session will be assessed.

  7. Patient satisfaction

    Time frame: 1 day

    Patient satisfaction with the treatment procedure on a scale from 1-5

  8. User satisfaction

    Time frame: 1 day

    User satisfaction assessed via a questionnaire

Other outcomes

  1. Change in wound size

    Time frame: 1 day

    Wound size will be compared before and after the debridement procedure

  2. Results of biopsy or smear

    Time frame: 1 day

    If performed during clinical routine, results of biopsy or smear will be assessed

  3. Removal of biofilm

    Time frame: 1 day

    Change in the presence of biofilm before and after debridement will be investigated using MolecuLightDX. This will only be done at one of the five participating sites.

Study contacts

Contact information is provided by the study sponsor or research team.

Claudia Feldkamp

CONTACT

[email protected]

+49 2631 99 7910

Sponsors and collaborators

Lead sponsor

Lohmann & Rauscher

Industry

Collaborators

  • AXCELLANT

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 31, 2025
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.